Silencing homeobox C6 inhibits colorectal cancer cell proliferation

Meiling Ji; Qingyang Feng; Guodong He; Liangliang Yang; Wentao Tang; Xinyuan Lao; Dexiang Zhu; Qi Lin; Pingping Xu; Ye Wei; Jianmin Xu

doi:10.18632/oncotarget.8703

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Silencing homeobox C6 inhibits colorectal cancer cell proliferation

Meiling Ji, Qingyang Feng, Guodong He, Liangliang Yang, Wentao Tang, Xinyuan Lao, Dexiang Zhu, Qi Lin, Pingping Xu, Ye Wei and Jianmin Xu _

PDF | HTML | How to cite

Oncotarget. 2016; 7:29216-29227. https://doi.org/10.18632/oncotarget.8703

Metrics: PDF 1886 views | HTML 4076 views | ?

Abstract

Meiling Ji1,*, Qingyang Feng1,*, Guodong He1,*, Liangliang Yang1,*, Wentao Tang1, Xinyuan Lao1, Dexiang Zhu1, Qi Lin1, Pingping Xu1, Ye Wei1, Jianmin Xu1

1Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

*These authors equally contributed to this work

Correspondence to:

Jianmin Xu, email: [email protected]

Ye Wei, email: [email protected]

Keywords: colorectal cancer, proliferation, HOXC6, autophagy, mTOR

Received: November 23, 2015 Accepted: March 28, 2016 Published: April 12, 2016

ABSTRACT

Homeobox C6 (HOXC6), a member of the homeobox family that encodes highly conserved transcription factors, plays a vital role in various carcinomas. In this study, we used a tissue microarray (TMA) consisting of 462 CRC samples to demonstrate that HOXC6 is more abundantly expressed in colorectal cancer (CRC) tissues than adjacent normal mucosa. Clinicopathological data indicated that higher HOXC6 expression correlated with poor overall survival and was associated with primary tumor location in the right colon, primary tumor (pT) stage 3/4 and primary node (pN) stage 1/2. Multivariate analysis showed that high HOXC6 expression was an independent risk factor for poor CRC patient prognosis. HOXC6 downregulation via lentivirus-mediated expression of HOXC6-targeting shRNA reduced HCT116 cell viability and colony formation in vitro, and reduced growth of subcutaneous xenografts in nude mouse. HOXC6 thus appears to promote CRC cell proliferation and tumorigenesis through autophagy inhibition and mTOR pathway activation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8703

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Silencing homeobox C6 inhibits colorectal cancer cell proliferation

Abstract